It is worth noting that there are studies already confirmed that inhibiting ACCs in the liver by using ND-630 (GS-0976) can significantly reduce 29% liver fat, hepatic steatosis, and markers of liver injury in NAFLD patients (101, 102), which further encourage the finding of ACCs inhibitors for therapeutic proposes. Here, ACCS is linked to fatty liver disease.